Unlock instant, AI-driven research and patent intelligence for your innovation.

Transgenic tumor infiltrating lymphocyte and application thereof

A lymphocyte and tumor infiltration technology, applied in the field of cell therapy, can solve the problems of TILs cells that are difficult to produce clinical curative effect and cell death

Pending Publication Date: 2021-03-19
赜誉(上海)生物科技有限公司
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

If the number of TILs cells is insufficient, and the tumor burden of the patient itself is relatively large, the insufficient number of TILs cells is expected to be difficult to produce significant clinical curative effect; 2. TILs cells in the tumor tissue of patients with advanced cancer are often suppressed by tumor suppressive immunity Inhibited by the microenvironment, many cells are in an exhausted state, and multiple in vitro expansions will lead to cell death

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transgenic tumor infiltrating lymphocyte and application thereof
  • Transgenic tumor infiltrating lymphocyte and application thereof
  • Transgenic tumor infiltrating lymphocyte and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] Example 1: Preparation of lentiviruses comprising anti-EGFR scFv-CD28 and anti-HER2 scFv-CD28 genes

[0088] 1. According to the reference (Journal of Immunological Methods. Volume 248, Issues 1–2, 1 February 2001, Pages 17-30. Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. MAbs. 2015; 7(6) :1058-71. Stability engineering of anti-EGFR scFvantibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach. Andreas Lehmann, Josephine H F Wixted, MaximV Shapovalov, Heinrich Roder, Roland L Dunbrack Jr , Matthew K Robinson.) selected the scFv sequence of EGFR antibody 2224 (see SEQ ID NO.: 1 for the nucleic acid sequence, and SEQ ID NO.: 2 for the amino acid sequence). According to references (Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibitan Increased Therapeutic Index against Tumors in Mice. Xiaojun Liu, ShuguangJiang, Chongyun Fang, Shi...

Embodiment 2

[0098] Example 2: Rapid Expansion of TILs

[0099] Select EGFR or HER2 positive tumors for TILs preparation. The basic steps are as follows:

[0100] The surgically obtained tumor tissue was cut into pieces of 1-2 mm in size, and transferred to a 24-well plate with 2 mL of complete medium, one tissue block per well. Complete medium components: RPMI-1640+10% human serum+2mM L-glutamine+25mM HEPES+10ug / mL gentamicin. It is also necessary to add 5000IU / mL IL-2 to the culture medium. Cultured in a cell culture incubator for 2-3 weeks, the TILs cells amplified from each well of a 24-well plate constituted a group. The expanded TIL cells were mixed. Rapid and massive expansion of TIL cells using irradiated allogeneic PBMCs. The irradiated PBMCs (340Gy) and TILs cells were obtained by centrifugation, and the cells were resuspended in 50 / 50 medium according to the ratio of 100:1, and cultured in the incubator. The final concentration of PBMCs was 1e6 / mL. The culture period is ab...

Embodiment 3

[0101] Example 3: Lentiviral transfection of TILs

[0102] Three days after TILs cells were reactivated, T cells were counted. Then adjust its cell concentration to 1×10 6 / ml, transferred to a six-well plate, and lentiviruses containing anti-EGFR scFv-CD28 and anti-HER2 scFv-CD28 DNA sequences were added to the culture wells of EGFR-positive tumor-derived TILs cells and HER2-positive tumor-derived TILs cells After transfection and expansion, the prepared TILs cells were named: anti-EGFR-CD28-TILs and anti-HER2-CD28-TILs. Untransfected TILs cells served as a negative control (control TILs). After transfection, the transfected and non-transfected TILs cells were cultured to a quiescent state.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a transgenic tumor infiltrating lymphocyte and application thereof. Specifically, the invention relates to the modified tumor infiltrating lymphocyte. The tumor infiltrating lymphocyte expresses a chimeric antigen receptor; the chimeric antigen receptor targets a tumor antigen; and the tumor antigen is EGFR and / or HER2. According to the transgenic tumor infiltrating lymphocyte and the application thereof, after TILs cells are in contact with tumor cells, the number of the TILs cells is remarkably increased, the activity and the killing capacity to the tumor cells are remarkably improved, the exhaustion of the TILs cells is reduced, and the TILs cells can be treated more effectively.

Description

technical field [0001] The present invention relates to the field of cell therapy, and more particularly to a transgenic tumor-infiltrating lymphocyte and use thereof. Background technique [0002] Cancer is a major disease that threatens human health. Although many new therapies and new drugs have been approved and approved by regulatory authorities in recent years, which has improved the survival of cancer patients to a certain extent, there is still a huge unmet clinical need in cancer treatment, especially in the treatment of advanced cancer. . A large category of cancers are solid tumors, accounting for about 90%. The other 10% are hematological-related malignancies. [0003] In cancer treatment, cell therapy represented by chimeric antigen receptor T cells (Chimeric Antigen Receptor-T; CAR-T) has shown good efficacy in the treatment of blood cancers, and two products have been approved by the FDA listed. However, CAR-T has failed to show significant efficacy in re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N5/10C12N15/867C07K19/00A61K39/00A61P35/00A61P35/02
CPCC07K14/7051C07K16/32C07K16/2863C12N5/0636C12N15/86A61K39/0011A61P35/00A61P35/02C12N2510/00C12N2740/15043C07K2319/02C07K2319/03C07K2319/33
Inventor 朱毅孟东踪家武
Owner 赜誉(上海)生物科技有限公司